aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, will report its second quarter 2022 financial results on August 15, 2022, after market close. Management will provide a corporate update and host a conference call at 5:00 PM EDT. The call will include discussions on operational updates related to their proprietary tRNA synthetase biology platform and the clinical-stage product candidate efzofitimod, targeting fibrotic lung disease. Interested participants can register for the call and webcast through the links provided.

Positive

• Focus on efzofitimod, a promising clinical-stage candidate targeting fibrotic lung disease.
• Leveraging a proprietary tRNA synthetase biology platform for first-in-class medicines.

Negative

• None.

Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report second quarter 2022 financial results and provide a corporate update after the market close on Monday, August 15, 2022. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Date: Monday, August 15, 2022
Time: 5:00 p.m. EDT / 2:00 p.m. PDT
Dial-In Registration: https://register.vevent.com/register/BI5d7604e9c0b54bbc88aaa9841cb67823
Webcast Registration: http://investors.atyrpharma.com/events-and-webcasts

Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team at investorrelations@atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

 

FAQ

When will aTyr Pharma report its second quarter 2022 financial results?

aTyr Pharma will report its second quarter 2022 financial results on August 15, 2022, after market close.

What is the focus of aTyr Pharma's research and development?

aTyr Pharma's research and development focus is on first-in-class medicines derived from its proprietary tRNA synthetase biology platform.

What time is the aTyr Pharma conference call on August 15, 2022?

The aTyr Pharma conference call is scheduled for 5:00 PM EDT on August 15, 2022.

How can I join the aTyr Pharma conference call?

Participants can register for the conference call via the provided dial-in registration link to receive access details.